Gefitinib

Gefitinib, 184475-35-2, Iressa, ZD1839, Irressat, ZD-1839, ZD 1839, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine, gefitinibum, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine, 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, NSC-759856, S65743JHBS, DTXSID8041034, DTXCID6021034, CHEBI:49668, NSC715055, 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine, N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(morpholin-4-yl)propoxy)quinazolin-4-amine, RefChem:58462, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide, L01XE02, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholin) propoxy)-4-quinazolinamine, 643-034-7, N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, gefitinib (zd1839), C22H24ClFN4O3, Gefitinib (GMP), MFCD04307832, N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine, CHEMBL939, Gefitinib [USAN], NCGC00159455-02, N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, 3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline, Iressa(TM), IRE, Iressa (TN), CCRIS 9011, CAS-184475-35-2, SR-00000000262, UNII-S65743JHBS, Gefitinib [USAN:INN:BAN], Irressat, , Gefitinib CRS, Iressa, , Gefitini, Iressa, GefitinibZD1839, Gefitinib (Standard), Iressa (AstraZeneca), nchembio866-comp14, Kinome_3321, Kinome_3322, GEFITINIB [INN], GEFITINIB [JAN], GEFITINIB [MI], GEFITINIB [VANDF], Gefitinib (ZD1839)?, GEFITINIB [MART.], GEFITINIB [WHO-DD], SCHEMBL7866, Gefitinib,ZD-1839,Iressa, GEFITINIB [EMA EPAR], KBioSS_002241, MLS003899193, CU-00000000396-1, Gefitinib - Bio-X trade mark, BDBM5447, cid_123631, GTPL4941, orb1309499, orb3141272, SCHEMBL4535121, SCHEMBL4535128, SCHEMBL4535134, Gefitinib (JP18/USAN/INN), GEFITINIB [ORANGE BOOK], GEFITINIB [EP MONOGRAPH], Gefitinib, >=98% (HPLC), SCHEMBL29351046, SCHEMBL29351336, GLXC-05820, HMS2089B19, HMS3244M21, HMS3244M22, HMS3244N21, HMS3295A21, HMS3413H08, HMS3654A07, HMS3677H08, HMS3714A05, HMS3748E17, HMS5079C05, Pharmakon1600-01502274, YWB97640, Tox21_111683, EBC-07543, Gefitinib for system suitability CRS, HY-50895G, HY-50895R, MSK159193, NSC759856, NSC800105, s1025, STK621310, AKOS000280752, Tox21_111683_1, AB20814, AC-1556, CCG-220642, CS-0124, DB00317, FG10816, KS-1204, NSC 759856, NSC-715055, NSC-800105, SDCCGSBI-0634411.P005, 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline, 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-, 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine, NCGC00159455-03, NCGC00159455-04, NCGC00159455-05, NCGC00159455-06, NCGC00159455-08, NCGC00159455-09, NCGC00159455-14, BCB03_000781, BG164498, HY-50895, SMR002204119, SY002154, CS-0622782, G0546, NS00006312, SW199108-4, D01977, EN300-123024, G-4408, K00240, AB01273954-01, AB01273954-02, AB01273954-03, AB01273954_04, F079438, Q417824, SR-00000000262-2, SR-00000000262-3, BRD-K64052750-001-16-7, BRD-K64052750-001-17-5, BRD-K64052750-001-22-5, BRD-K64052750-001-23-3, Gefitinib, EuropePharmacopoeia (EP) Reference Standard, Z1546610485, 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline, Gefitinib for system suitability, EuropePharmacopoeia (EP) Reference Standard, N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4 -ylpropoxy)quinazolin-4-amine, (3-CHLORO-4-FLUORO-PHENYL)-[7-METHOXY-6-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-4-YL]-AMINE